Marksans Pharma’s arm gets approval from USFDA for Omeprazole Delayed-Release Tablets

08 Aug 2025 Evaluate

Marksans Pharma’s wholly owned subsidiary -- Marksans Pharma Inc. has received the final approval for Abbreviated New Drug Application (ANDA) from United States Food and Drug Administration (USFDA) for Omeprazole Delayed-Release Tablets, 20 mg (OTC). 

This product is bioequivalent to the reference listed drug (RLD), Prilosec Delayed-Release Tablets, 20 mg (OTC), of AstraZeneca Pharmaceuticals LP, NDA - 021229. Omeprazole is used to treat heartburn and certain other conditions caused by too much acid in the stomach.

Marksans Pharma is engaged in Research, Manufacturing & Marketing of generic pharmaceutical formulation in the global markets.

Marksans Pharma Share Price

183.95 -3.95 (-2.10%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×